Overview

Follow-up of NAFLD Patients With MRI-PDFF

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an important role in the pathogenesis of both NAFLD and T2DM.
Phase:
Phase 4
Details
Lead Sponsor:
Asmaa Abdelfattah Elsayed
Treatments:
Empagliflozin
Pentoxifylline
Ursodeoxycholic Acid